Tislelizumab plus GemOx and Lenvatinib as a Conversion Therapy Regimen for Potentially Resectable BTCs

2022 Year in Review: Cholangiocarcinoma — January 4, 2023

Although biliary tract cancer (BTC) can only be cured by surgery, this is not an option for all patients. Converting locally unresectable patients to resectable status with conversion therapy can improve overall survival. One potential conversion therapy regimen includes tislelizumab, an anti–PD-1 monoclonal antibody. The combination of lenvatinib and tislelizumab has demonstrated encouraging antitumor and safety results in patients with advanced hepatocellular carcinoma. This study evaluated a potential role for a combination of lenvatinib, tislelizumab, and gemcitabine/oxaliplatin (GemOx) in potentially resectable BTC. Results were shared at the 2022 ESMO congress.

The combination of therapies was evaluated in a prospective, single-center, single-arm, phase 2 study. To be enrolled, patients had to have potentially resectable, locally advanced BTC and no previous systemic treatment. They also had to be Child-Pugh class A or B and have an ECOG performance status score of 0 or 1. Dosing was as follows: GemOx followed by intravenous tislelizumab (200 mg every 3 weeks) and lenvatinib (8 mg/kg orally daily) for ≤7 cycles. If at this point the cancer remained unresectable, patients continued to receive tislelizumab and lenvatinib.

The data reported here include evaluations of 25 patients. The median age of the patients was 59.7 years (range, 33-77 years); 44% of the patients were men. All patients had an ECOG performance status score of 1, and a large majority (92%) of the patients were Child-Pugh class A. The median tumor size was 5.3 cm (range, 1.57-11.036 cm); 36% of patients had intrahepatic metastases, 12% had extrahepatic metastases, and 60% had lymph node metastases.

The median duration of therapy before surgery was 3.44 cycles (range, 2-8 cycles). After treatment, 13 (52%) patients had received R0 resection, 2 (8%) patients received intraoperative radiotherapy, and 1 (4%) patient had complete pathological response. In terms of clinical/pathological outcomes, objective response rate was 56%, disease control rate was 92%, conversion rate was 84%, and surgery rate was 60%. Before treatment, 80% of patients had cancer antigen 19.9 levels >37 U/mL, and after treatment, this was reduced to 60% of patients.

No patients experienced severe complications. Grade 3 treatment-related adverse events included leukopenia, thrombocytopenia (3 patients each), diarrhea, and hypertension (2 patients each).

Based on these results, the authors concluded that the combination of tislelizumab with lenvatinib and GemOx is a promising therapeutic regimen for patients with potentially resectable locally advanced BTC.

Sources: Dongming L, Xihao Z, Han M, et al. A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and GEMOX regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers. Ann Oncol. 2022;33(suppl 7):S570.

Dongming L, Xihao Z, Han M, et al. A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and GEMOX regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers. European Society for Medical Oncology Congress 2022. Abstract 65P.

Related Items

Cross-Comparison of Clinical Trials Assessing Futibatinib and Pemigatinib versus Chemotherapy in Patients with CCA and FGFR2 Fusion or Other Rearrangements
2022 Year in Review: Cholangiocarcinoma
A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.
Utility of Liquid Biopsy for Identification of Molecular Alterations in Solid Tumors
2022 Year in Review: Cholangiocarcinoma
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma.
Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial
2022 Year in Review: Cholangiocarcinoma
Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
NALIRICC Study of Nanoliposomal Irinotecan Combination Therapy in Metastatic BTC
2022 Year in Review: Cholangiocarcinoma
The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer.
Health-Related QOL Study in Patients with CCA
2022 Year in Review: Cholangiocarcinoma
Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies.
Updated Analysis of the LUC2001 Study
2022 Year in Review: Cholangiocarcinoma
Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations.
Biliary Tract Cancers: Is Laparoscopic Liver Resection Adequate?
2022 Year in Review: Cholangiocarcinoma
Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection.
The Future of Neoadjuvant Chemotherapy for iCCA
2022 Year in Review: Cholangiocarcinoma
Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.
Mayo Clinic Study Assessed Impact of Neoadjuvant Chemoradiation in Patients with Unresectable Perihilar CCA
2022 Year in Review: Cholangiocarcinoma
Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.
Impact of Liver-Directed Radiation Therapy in Patients with Metastatic iCCA
2022 Year in Review: Cholangiocarcinoma
A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: